Business Blockbuster - Helpng business to be more visible on Google

Daily Bulletin

Yicura BioMed Holds Pre-Launch Preparation Meeting and IDMC Kick-off Meeting for ICVAX-201 Clinical Project

ICVAX® Phase II Clinical Study Enters Key Preparation Stage

BEIJING, CHINA – Media OutReach Newswire – 19 November 2026 – Yicura BioMed held the Pre-launch Preparation Meeting and the Independent Data Monitoring Committee ("IDMC") Kick-off Meeting for the ICVAX-201 clinical project in Beijing today.

ICVAX® is a therapeutic HIV DNA vaccine candidate developed based on Yicura BioMed's PD-1-enhanced DNA vaccine platform. The meeting focused on discussions regarding the implementation preparations, study protocol, and independent data monitoring arrangements for ICVAX® Phase II clinical trial, laying the foundation for the subsequent smooth progress of the project.

ICVAX-201 is a National Medical Products Administration ("NMPA") approved registrational Phase II clinical trial, which is a cross-border, multi-centre, randomized, double-blind, placebo-controlled clinical trial involving a total of 5 clinical trial centres in Chinese mainland and Hong Kong, with Prof. Fujie ZHANG of Beijing Ditan Hospital, Capital Medical University, who is also the Leader of the AIDS Clinical Expert Working Group of the National Health Commission, serving as the Principal Investigator. The primary objective of the trial is to explore the immune protection mechanism of ICVAX®, and the secondary objectives are to evaluate its efficacy in suppressing HIV-1 RNA viral load, as well as the safety of its combination with antiretroviral therapy ("ART") in controlling HIV-1 infection following analytical treatment interruption ("ATI"). Participating centres in Chinese mainland include Beijing Ditan Hospital, Capital Medical University; Beijing Youan Hospital, Capital Medical University; Guangzhou Eighth People's Hospital; and The Third People's Hospital of Shenzhen. The participating centre in Hong Kong is the Phase I Clinical Trial Centre of The Chinese University of Hong Kong. The centres will collaborate to advance the study and explore the potential of ICVAX® in the field of functional cure for HIV.

Dr. Xia JIN, Co-Founder and Chief Executive Officer of Yicura BioMed, stated that the completion of NMPA approved registrational Phase I clinical trial of ICVAX® and its entry into the preparation stage for the Phase II clinical trial marks an important step forward in the project's clinical development. Yicura BioMed will work closely with all partners, strictly execute the study protocol, implement quality management requirements, and promote the standardized and orderly progress of the Phase II clinical study.

Professor Zhiwei CHEN, Tenured Chair Professor of Immunology and Immunotherapy, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, and Suen Chi-Sun Professor in Clinical Science, who is also as the inventor of the PD-1-enhanced DNA vaccine technology and the Principal Scientific Advisor of Yicura BioMed, introduced the R&D background of ICVAX®. Focusing on its technical foundation, mechanism of action, and R&D strategy, he elaborated on the scientific basis for conducting subsequent clinical studies of ICVAX®.

Professor Hongzhou LU of The Third People's Hospital of Shenzhen, the Principal Investigator of the ICVAX® Phase I clinical trial, presented the results of the Phase I clinical trial and the progress of the Phase I extension investigator-initiated trial ("IIT"). In the first-in-human Phase I clinical trial of ICVAX®, all 45 subjects completed follow-up, and the results demonstrated promising safety and immunogenicity. In the subsequent treatment interruption observation, after receiving two rounds of booster in the enrolled 10 subjects, the proportion achieving sustained virological suppression after treatment interruption increased from 10% (1/10) to nearly 30% (2/7) in the second stage. Of the 2 subjects enrolled in the third stage, 1 subject maintained sustained virological suppression for more than 70 weeks (17.5 months) without restarting ART.

Professor Fujie ZHANG, Principal Investigator of the ICVAX® Phase II clinical trial, introduced the Phase II clinical study protocol. Participating experts conducted in-depth exchanges on the study design, implementation arrangements, and key issues in the study.

The IDMC Kick-Off meeting was held concurrently during the conference, during which the committee members and working protocol were introduced, and a letter of appointment presentation ceremony was held. In compliance with the protocol, the IDMC will independently review the clinical trial progress and relevant data and provide professional recommendations on the protection of subject safety and the implementation of the study.

Hashtag: #Yicura #醫克生物



The issuer is solely responsible for the content of this announcement.

About Yicura BioMed (formerly known as Immuno Cure)

Yicura BioMed is a clinical-stage biotechnology group based in Hong Kong Science Park, focusing on the research and development of immunotherapies for cancers, inflammations, and infectious diseases based on its patented PD-1-enhanced DNA vaccine and anti-Δ42PD1 antibody platforms.

To learn more about Yicura, please visit:

Business News

The Growing Demand for Durable Plastic Packaging Supplies Across Australia

Why Do Australian Businesses Need Reliable Plastic Packaging Supplies? Businesses need packaging that can withstand everyday handling, storage, and distribution without creating avoidable delays. Pla...

Daily Bulletin - avatar Daily Bulletin

Office Cleaning Melbourne: Choosing the Right Scope for Your Office

A well-planned office cleaning Melbourne arrangement starts with a clear understanding of the premises and the people who use it. An office may include private work areas, shared desks, reception, mee...

Daily Bulletin - avatar Daily Bulletin

How Businesses Can Prepare for Unexpected Power Outages

Power failures can occur quickly. The supply may be interrupted by bad weather, issues with the electricity network, damaged equipment or local construction work. This can be just a hassle for a fam...

Daily Bulletin - avatar Daily Bulletin

How Chatswood Tutoring Can Fit Into a Student’s Weekly Routine

Create a Predictable Weekly Structure A consistent weekly routine can make study easier to manage when students are balancing several subjects. Chatswood tutoring can provide a fixed learning point a...

Daily Bulletin - avatar Daily Bulletin

The Rise of Digital Marketplaces in the Australian Trade Sector

For decades, the Australian trade and construction sector operated almost entirely on word-of-mouth recommendations and local community networks. Small business owners typically relied on local newspa...

Daily Bulletin - avatar Daily Bulletin

How Immigration Lawyers Can Help

Introduction Visa decisions can shape employment, family life, study plans, travel, and future residence. A small omission can lead to delay, added expense, or refusal. Immigration lawyers assess l...

Daily Bulletin - avatar Daily Bulletin

How Industrial Drying Equipment Supports Efficient Processing

Many industrial processes require moisture to be removed from compressed air, products or process materials before they move to the next stage. Excess moisture can affect equipment performance, produc...

Daily Bulletin - avatar Daily Bulletin

Practical Ways a Whiteboard Can Improve Workplace Communication

Effective communication helps teams stay organised, share ideas and keep track of important information. While digital tools are now common in many workplaces, a whiteboard continues to provide a simp...

Daily Bulletin - avatar Daily Bulletin

Designing Eco-Friendly Custom Water Bottles for Your Next Event

The Evolution of Sustainable Event Merchandise Event planning has undergone a massive transformation over the last decade. Gone are the days when organizers could hand out cheap, single use plastic...

Daily Bulletin - avatar Daily Bulletin

The Daily Magazine

Work Boots vs Safety Shoes: Which Footwear Is Right for Your Workplace?

Not every job calls for a heavy pair of boots. Walk through a modern warehouse, factory floor or dis...

Master Bedroom Wall Decor Guide: Sizing, Layouts and Styling Ideas for Every Space

The main bedroom is often the last room in the house to get any attention. The living room gets the ...

What to Consider Before Installing a Built-In Wardrobe

Living in a modest home teaches you a lot. You learn how to keep a small kitchen tidy, where to hi...

Top 5 Mortgage Brokers in Sydney: How to Choose the Right One in 2027

Finding a mortgage broker in Sydney is not particularly difficult. Finding one who understands your ...

How Much Life Does Your Roof Have Left? Recognizing When Replacement Becomes Necessary

A roof can age quietly for years. From the street, everything may look reassuringly ordinary, even w...

How Australian Drivers Can Make Their Cars Harder to Steal

Most people don't think much about car theft until it happens to them, or to someone they know. Th...

The Short-Term Rental Rules Australian Owners Can’t Afford to Guess At

A holiday let looks simple from the outside: a spare property, a listing, some guests. Underneath ...

The Risks Of Removing Ear Wax Without Professional Guidance

Ear wax is an essential component of the hygiene process since it acts as a barrier between the ea...

Plumbing Call-Out Fees in Perth Explained

When you hire a plumber to fix a problem with a dripping tap, leaking pipe, or whatever it might be...